Fig. 2.

Proportions of patients without metabolic syndrome at baseline who developed metabolic syndrome or any component criterion of metabolic syndrome.^a,b, ^aOdds ratio (95% CI) for the development of MetS during treatment with OLZ/SAM vs olanzapine, at the last on-treatment assessment, in those without MetS at baseline: 0.55 (0.31, 0.99). ^bThe proportion of patients who developed metabolic syndrome or who developed individual metabolic syndrome parameter criteria were compared using a logistic regression model based on observed data at the patients’ last on-treatment assessments. The model included treatment, race (black, non-black), and age group (<30 years, ≥30 years) as factors, and baseline body mass index as covariate. HDL, high-density lipoprotein; MetS, metabolic syndrome; OLZ/SAM, combination of olanzapine and samidorphan.